Results
ADVERSE EVENTS, MINOR
Of the 106 participants recruited to the trial, 86 completed the 12-month study period (39 males and 47 females). Of the 20 patients who did not complete, six patients developed adverse events, which necessitated termination of their medication and their participation in the study and 14 participants withdrew from the study due to time constraints, including both patients diagnosed with the herpetiform type of RAS. In the betamethasone group 29 out of 35 participants finished the 12 months trial (9 males and 20 females; 17 minor and 12 major RAS). In the colchicine group, 26 out of 35 completed the clinical trial (14 males and 12 females; 18 minor and 8 major RAS) and in the mixed therapy group 31 out of 36 completed the clinical trial (16 males and 15 females; 11 minor and 20 major RAS) (Fig. 
Diagram of the number of participants at each stage of the clinical trial. Patients screened for the clinical trial: diagnosis and treatment modality assigned and reasons for exclusion. Patients completing the clinical trial: diagnosis, treatment modality and incidence of side effects (201 screened, 106 randomised and 86 completed 12 months trial)